We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Fuc3.5
Fucoidan Research
Too few graded studies
38 peer-reviewed studies
What the evidence says
Too few graded studies
Fucoidan doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 2007–2026 with a typical study size of 118 participants.
Based on 38 studies · 1 meta-analysis · 17 RCTs · 118 total participants
Longevity & agingOne small trial in older adults improved antibody response to flu vaccination. Lifespan and healthspan signals come from invertebrate and animal models only · Unknown
Too few graded studies1 study
Safety profile
Too few graded studies1 study
Active research area
30 studies in the last 5 years · Latest meta-analysis: 2025
200720162026
1Meta-AnalysisCited 2×2025
In plain English: Consuming over 3 g/day of whole edible algae, especially Spirulina, for at least 12 weeks significantly lowers BP, particularly in those with elevated levels.
Casas-Agustench P, Mínguez S, Brookes Z, Bescos R. · Journal of human nutrition and dietetics : the official journal of the British Dietetic Association (2025)
Edible algae intake significantly reduced systolic BP (SBP: -2.05 mmHg; 95% CI: -3.80, -0.31; p = 0.022) and diastolic BP (DBP: -1.87 mmHg; 95% CI: -3.10, -0.64; p = 0.001).
Heterogeneity was high for SBP (Q-value: 230; I 2 = 75%; p < 0.001) and moderate for DBP (Q-value: 102; I 2 = 68%; p < 0.001).
Spirulina was the most effective algae, reducing SBP by -5.28 mmHg (p = 0.032) and DBP by -3.56 mmHg (p = 0.044).
In plain English: This review provides an overview of the antidiabetic potential of brown seaweeds, with a particular focus on the mechanisms of action of their major bioactive compounds, including fucoidan, alginate, phlorotannins, and fucoxanthin.
Jung UJ, Kim SR. · International journal of molecular sciences (2026)
Brown seaweeds are increasingly recognized as promising marine-derived functional foods because they contain structurally unique bioactive compounds, including fucoidan, alginate, phlorotannins, and fucoxanthin.
Brown seaweed-derived bioactive compounds have also been reported to improve abnormal lipid metabolism, a key pathological process implicated in metabolic disorders associated with T2D, including MASLD.
In plain English: Overall, this review provides a well-balanced, evidence-based assessment of aquaculture-derived marine bioactive as potential neurotherapeutic agents.
Patwekar F et al. · Brain research (2026)
The review even discusses emerging and enabling technologies like brain organoids, multi-electrode array platforms, omics-based profiling, and artificial intelligence assisted drug discovery, which are increasingly utilized to refine mechanistic understanding and optimize marine-derived products.
Importantly, current evidence stay largely preclinical, with little human studies and a lack of validated receptor-specific biomarkers.
Overall, this review provides a well-balanced, evidence-based assessment of aquaculture-derived marine bioactive as potential neurotherapeutic agents.
In plain English: Future research focused on establishing precise structure-activity relationships and further elucidating its action via the gut-brain axis will be important for translating this promising natural compound into a validated clinical therapy for neurological disorders.
Wu Q, Hui X, Cui A, Meng X. · Drug development research (2026)
Its therapeutic efficacy relies on potent anti-inflammatory activity through the modulation of glial cell activation, significant antioxidant effects by neutralizing reactive oxygen species and reinforcing endogenous defenses, and direct anti-apoptotic actions that inhibit programmed cell death.
Furthermore, this review highlights the pivotal and emerging role of the microbiota-gut-brain axis as a key regulator of the neuroprotective effects of fucoidan, whereby its prebiotic activity in the gut instigates systemic benefits that extend to the central nervous system.
By consolidating findings from diverse preclinical models of ischemic stroke, traumatic brain injury, Alzheimer's disease, and Parkinson's disease, we conclude that fucoidan is a powerful, multitarget agent.
In plain English: We conclude that fucoidan represents a natural product derived from traditional wisdom, with a defined molecular mechanism and translational potential, offering a promising complementary strategy for the comprehensive management of CKD.
Xin P, Ge C, Tang Y, He Y, Fu B. · Frontiers in pharmacology (2026)
This central action not only directly restores the renal charge barrier and reduces proteinuria but also, by stabilizing endothelial function, systemically inhibits the inflammation and fibrosis cascades triggered by glycocalyx injury.
The efficacy of fucoidan in diverse preclinical models, coupled with clinical trial evidence for fucoidan-based drugs in human CKD patients, collectively supports the validity of a glycocalyx-targeted therapeutic strategy.
We conclude that fucoidan represents a natural product derived from traditional wisdom, with a defined molecular mechanism and translational potential, offering a promising complementary strategy for the comprehensive management of CKD.
In plain English: These multifaceted actions position fucoidan as a promising novel therapeutic strategy for mitigating post-MI inflammation and promoting cardiac recovery.
Zou Y, Li Y, Kong M, Yu Y. · Frontiers in bioscience (Landmark edition) (2026)
Specifically, it enhances the abundance of beneficial gut bacteria, boosts short-chain fatty acids (SCFA) production, and reduces bacterial endotoxin translocation.
Additionally, fucoidan directly inhibits inflammatory signaling pathways, decreases pro-inflammatory cytokine secretion, and protects cardiomyocytes through antioxidant effects.
These multifaceted actions position fucoidan as a promising novel therapeutic strategy for mitigating post-MI inflammation and promoting cardiac recovery.
In plain English: Collectively, current evidence, derived largely from preclinical studies, supports the potential of fucoidan as a promising multifunctional adjuvant for cancer combination therapy, while further standardization, mechanistic studies, and clinical validation will be essential for its successful translation into clinical practice.
Jang Y. · International journal of molecular sciences (2026)
In this review, we summarize the biological characteristics that make fucoidan an attractive combination partner and provide a comprehensive overview of current evidence regarding fucoidan-based combination strategies for cancer therapy.
We further discuss the molecular mechanisms underlying these combination effects, including the regulation of apoptosis, autophagy, tumor microenvironment remodeling, and oncogenic signaling pathways associated with therapeutic resistance.
Although combinations with conventional anticancer therapies have been extensively investigated, studies involving natural bioactive compounds remain remarkably limited, highlighting an important opportunity for future research.